Skip to main content

Table 2 IC50 of Sorafenib and nanaomycin in Hep3B naïve cells and Hep3Bresistant cells

From: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation

Drugs (μM)Inhibitory concentration, IC50 (μM)
Hep3B naive cellsHep3B resistant cells
Sorafenib9.56 ± 1.7715.7 ± 3.11
Nanaomycin5.56 ± 3.197.48 ± 5.92
Sorafenib + Nanaomycin 26.38 ± 0.817.71 ± 0.88
Sorafenib + Nanaomycin 53.01 ± 0.754.68 ± 0.95
Sorafenib + Nanaomycin 101.42 ± 0.202.06 ± 0.43